IMU Biosciences
Last verified 2026-06-05. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $53.0Mattributed |
|---|---|
| Latest round | series-a, $53.0M, 2026-06-01attributed |
| Founded | unknown |
| Headquarters | London |
| Industry | healthtech |
| Stage | series-a |
| Website | imubiosciences.com |
IMU Biosciences runs an HD Immunology platform that analyzes blood samples to map 2,500 immune cell subsets and over 100 million data points in real time. It serves clinical research groups, pharma, biotech, and diagnostics firms. Its edge is the resolution and scale of its immune mapping from just 2 milliliters of blood.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-06-01 | series-a | $53.0M | undisclosed |
Detected tech stack
none
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $53.0M | attributed | rss-feeds named as publisher. No document URL on file. |
| Total raised $53.0M | attributed | rss-feeds named as publisher. No document URL on file. |
| Company existence | self-reported | imubiosciences.com, read 2026-06-05 |
| Description | self-reported | imubiosciences.com, read 2026-06-05 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.